« Back to Record
Citation APA

Jastorff, A., Gymnopoulou, E., Salas, J., Merrall, E., Buntinx, E., Martin, C., Askling, H. H., Schenkenberger, I., Yuste, A. C., Smith, W., Sotolongo, R., Von Engelhardt, C., Bastian, A. R., Comeaux, C., Ligtenberg, N., Callendret, B., & Heijnen, E. (2025). Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. Vaccine, 43, 126514. doi:10.1016/j.vaccine.2024.126514


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/387443

Jastorff, A., Gymnopoulou, E., Salas, J., Merrall, E., Buntinx, E., Martin, C., Askling, H. H., Schenkenberger, I., Yuste, A. C., Smith, W., Sotolongo, R., Von Engelhardt, C., Bastian, A. R., Comeaux, C., Ligtenberg, N., Callendret, B., & Heijnen, E. (2025). Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. Vaccine, 43, 126514. doi:10.1016/j.vaccine.2024.126514